Clinical data | |
---|---|
Trade names | Istodax |
Other names | FK228; FR901228; Istodax |
MedlinePlus | a610005 |
License data |
|
Routes of administration | Intravenous infusion |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | Not applicable (IV only) |
Protein binding | 92–94% |
Metabolism | Liver (mostly CYP3A4-mediated) |
Elimination half-life | 3 hours |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.211.884 |
Chemical and physical data | |
Formula | C24H36N4O6S2 |
Molar mass | 540.69 g·mol−1 |
3D model (JSmol) | |
| |
| |
(what is this?) (verify) |
Romidepsin, sold under the brand name Istodax, is an anticancer agent used in cutaneous T-cell lymphoma (CTCL) and other peripheral T-cell lymphomas (PTCLs). Romidepsin is a natural product obtained from the bacterium Chromobacterium violaceum, and works by blocking enzymes known as histone deacetylases, thus inducing apoptosis.[2] It is sometimes referred to as depsipeptide, after the class of molecules to which it belongs. Romidepsin is branded and owned by Gloucester Pharmaceuticals, a part of Celgene.[3]
NCI
was invoked but never defined (see the help page).Gloucester
was invoked but never defined (see the help page).